Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

61 citing papers in PubMed.

1. Patient characteristics to guide personalized treatment decisions and prognostication in hepatocellular carcinoma.Hepatic oncology · 2026
   Review
2. STRIDE sustained an overall survival benefit with safety profiles in unresectable hepatocellular carcinoma at 5-year follow-up.Hepatobiliary surgery and nutrition · 2026
   Article
3. Preclinical exploration and current clinical applications of immunotherapeutic strategies for hepatocellular carcinoma.Frontiers in immunology · 2026
   Review
4. Novel Therapeutics for Hepatocellular Carcinoma.Clinics in liver disease · 2025
   Review
5. Exosomal biomarkers and immune checkpoint inhibitors: advancements and future prospects.Cancer cell international · 2025
   Review
6. Nanoparticle-based therapeutic strategies for chronic liver diseases: Advances and insights.Liver research (Beijing, China) · 2025
   Review
7. Proposal of discontinuation criteria of atezolizumab plus bevacizumab after curative conversion therapy for unresectable early-to-intermediate-stage hepatocellular carcinoma: a multicenter proof-of-concept study.Journal of gastroenterology · 2025
   Article
8. Targeting immune checkpoints in hepatocellular carcinoma therapy: toward combination strategies with curative potential.Experimental hematology & oncology · 2025
   Review
9. Targeting Metabolism: Innovative Therapies for MASLD Unveiled.International journal of molecular sciences · 2025
   Review
10. Tracing specificity of immune landscape remodeling associated with distinct anticancer treatments.iScience · 2025
    Article
11. The Predictive Significance of Interleukin-2 Receptor in Patients with Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2025
    Article
12. Leveraging artificial intelligence to validate traditional biomarkers and drug targets in liver cancer recovery: a mini review.Frontiers in pharmacology · 2025
    Review
13. Multimodal combination regimen for a patient with advanced huge hepatocellular carcinoma: a case report.Translational gastroenterology and hepatology · 2025
    Article
14. A Notch signaling pathway-related gene signature: Characterizing the immune microenvironment and predicting prognosis in hepatocellular carcinoma.Journal of translational internal medicine · 2024
    Article
15. Real-world status, efficacy and prognosis analysis of first-line treatment for unresectable hepatocellular carcinoma in patients treated at multiple centres.Annals of medicine · 2024
    Article
16. AAV-mediated combination gene therapy of inducible Caspase 9 and miR-199a-5p is therapeutic in hepatocellular carcinoma.Cancer gene therapy · 2024
    Article
17. Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy.Journal of translational medicine · 2024
    Review
18. Yttrium-90 Induces an Effector Memory Response with Neoantigen Clonotype Expansion: Implications for Immunotherapy.Cancer research communications · 2024
    Article
19. Complete Pathologic Response to Gemcitabine and Oxaliplatin Chemotherapy After Prior Therapies in a Patient With Hepatocellular Carcinoma and Peritoneal Metastases Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.World journal of oncology · 2024
    Article
20. An Investigative Analysis of Therapeutic Strategies in Hepatocellular Carcinoma: A Raetrospective Examination of 23 Biopsy-Confirmed Cases Emphasizing the Significance of Histopathological Insights.Cancers · 2024
    Article

1 more citing papers are in PubMed but not listed here.

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.